Novavax reported $1.76B in Current Assets for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Assets Change
Adma Biologics ADMA:US USD 224.1M 1.32M
Agenus AGEN:US USD 251.43M 37.5M
Astrazeneca AZN:US USD 20.22B 693M
AstraZeneca AZN:LN USD 20.22B 693M
Genocea Biosciences GNCA:US USD 24.41M 17.41M
Geron GERN:US USD 222.07M 5.3M
GlaxoSmithKline GSK:LN GBP 20.25B 33.94B
Mannkind MNKD:US USD 218.38M 24.9M
Minerva Neurosciences NERV:US USD 44.84M 5.2M
Moderna Inc MRNA:US USD 14.3B 734M
Novartis NVS:US USD 36.95B 1.19B
Novavax NVAX:US USD 1.76B 376.04M
Pain Therapeutics PTIE:US USD 183.27M 20.93M
Peregrine Pharmaceuticals PPHM:US USD 180.64M 612K
Sarepta Therapeutics SRPT:US USD 2.63B 156.63M
Tg Therapeutics TGTX:US USD 182.92M 19.64M